In this phase 3 trial, researchers aimed to study the efficacy of tumor bed boost and moderately hypofractionated whole breast irradiation in patients with non-low-risk DCIS.

Some cancers may not require immediate treatment, from prostate cancer to thyroid tumors. Medical experts share when ...

Innovative smart pill bottles significantly enhance adherence to oral adjuvant endocrine therapy in early-stage breast cancer, noted Steven Manobianco, MD. With real-world evidence suggesting that ...

LAGUNA HILLS, Calif., Dec. 10, 2025 /PRNewswire/ -- Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced results from the first ...

Veralto (VLTO) said Tuesday it agreed to acquire environmental water measurement and monitoring solutions company In-Situ for $435 million. Veralto (VLTO) said In-Situ's portfolio of water quality ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The acquisition is Veralto's ...

Invasive lobular carcinoma accounts for about 10% of breast cancer diagnoses. Its incidence is increasing at the rate of 2.8% annually -- more than triple that of other breast cancers combined. This ...

Doctors may be able to spare patients unnecessarily aggressive breast cancer treatments by collecting and testing cancer cells in patients' blood, research from the University of Michigan and the ...

CLEVELAND — Barbara Sandon Norris thought she had every reason to celebrate in May. Seven years cancer-free with a clean mammogram, the 72-year-old Cleveland woman almost skipped her routine follow-up ...

A polygenic risk score (PRS) may help identify women who are at a greater risk of developing a future breast cancer after treatment for in situ breast disease, a retrospective study suggests. The ...